Sun Pharmaceutical Recalls Subpotent Absorica LD Isotretinoin Capsules
Sun Pharmaceutical Industries is recalling Absorica LD (Isotretinoin) capsules because the active ingredient content was lower than the required specification limit.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates the product is not likely to cause adverse health consequences. The hazard is a subpotent drug (lower than specification), which is a quality issue rather than a direct safety hazard like contamination or mislabeling of a dangerous substance.
Plain-English summary
Sun Pharmaceutical Industries, Inc. is recalling Absorica LD (Isotretinoin) Capsules 30 mg USP. The recall involves 47,520 prescription packs distributed nationwide in the USA. The specific lot affected is 17F28AA with an expiration date of 1/2020.
The recall was initiated because the isotretinoin content in the product was found to be lower than the specification limit during routine product monitoring. This condition is classified as a subpotent drug issue.
Consumers and healthcare providers should check their inventory for the specific lot number and expiration date listed above. If the product matches the recalled lot, it should be returned to the pharmacy or point of distribution for a refund or replacement.
The recalled product
- Product
- ABSORICA LD (ISOTRETINOIN)
- Brand
- ABSORICA LD
- Manufacturer
- Sun Pharmaceutical Industries, Inc.
- Category
- Drug — Prescription Drug
- Hazard
- Affected units
- 47,520
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: 17F28AA
- Exp 1/2020
UPCs (1)
- 310631117313
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ABSORICA LD
- ModerateRanbaxy Recalls Absorica LD Isotretinoin Capsules Due to Undeclared Dye
FDA (Drugs) · 2015-08-12
Same manufacturer · Sun Pharmaceutical Industries, Inc.
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · subpotent drug
See all →- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02